Cargando…
Targeting Syndecan-1, a molecule implicated in the process of vasculogenic mimicry, enhances the therapeutic efficacy of the L19-IL2 immunocytokine in human melanoma xenografts
Anti-angiogenic therapy of solid tumors has until now failed to produce the long lasting clinical benefits desired, possibly due to the complexity of the neoangiogenic process. Indeed, a prominent role is played by “vasculogenic” or “vascular” mimicry (VM), a phenomenon in which aggressive cancer ce...
Autores principales: | Orecchia, Paola, Conte, Romana, Balza, Enrica, Pietra, Gabriella, Mingari, Maria Cristina, Carnemolla, Barbara |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741939/ https://www.ncbi.nlm.nih.gov/pubmed/26460958 |
Ejemplares similares
-
L19-IL2 Immunocytokine in Combination with the Anti-Syndecan-1 46F2SIP Antibody Format: A New Targeted Treatment Approach in an Ovarian Carcinoma Model
por: Orecchia, Paola, et al.
Publicado: (2019) -
Vasculogenic mimicry
por: Pandiar, Deepak, et al.
Publicado: (2023) -
Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy
por: Mortara, Lorenzo, et al.
Publicado: (2018) -
Tyrosinase suppresses vasculogenic mimicry in human melanoma cells
por: Kamo, Hiroki, et al.
Publicado: (2022) -
Vasculogenic mimicry structures in melanoma support the recruitment of monocytes
por: Tan, Lih Y., et al.
Publicado: (2022)